Drug intelligence / Profile preview

SDV2105

Development stage: Preclinical
Lead developer: SYNDIVIA
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics

Overview

SDV2105 is an antibody-drug conjugate (ADC) currently in the discovery and preclinical stages of development by SYNDIVIA. The drug is constructed using SYNDIVIA's proprietary GeminiMab technology platform, which is designed for the site-specific conjugation of drugs to antibodies to create highly stable and homogeneous ADCs with an improved therapeutic index. As of the current pipeline disclosures, the specific biological target, cytotoxic payload, and primary disease indications for SDV2105 remain undisclosed by the developer.

Beyond the preview

Go deeper on SDV2105.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SDV2105.

Explore the full profile